Schwartz, George
April 1959
Angiology;Apr1959, Vol. 10 Issue 2, p115
Academic Journal
1. .V series of 38 patients was treated with a new quinidine compound, quinidine polygalacturonate. 2. The dosage administration was similar to that used with older, conventional quinidine therapy. 3. The incidence of conversion of the arrhythmia to normal sinus rhythm was eminently satisfactory. 4. An outstanding desirable feature of the new compound was the complete absence of side reactions in this .series, even when large initial dosage was used. 5. Because of the ease of therapeutic usage. well known beneficial effects and lack of limiting gastrointestinal side reactions, we recommend quinidine polygalacturonate (Cardioquin) whenever quinidine is indicated as an antiarrhythmic agent.


Related Articles

  • Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. Saksena, Sanjeev // Journal of Interventional Cardiac Electrophysiology;Jan2012, Vol. 33 Issue 1, p1 

    The author reflects on the proliferation of randomized clinical trials (RCTs) of antiarrhythmic therapies and the optimization of health care resource deployment. He suggests the significance of RCTs in evidence-based medicine and practice guidelines in cardiac arrhythmias. He discusses the...

  • Quinidine.  // Reactions Weekly;7/23/2005, Issue 1061, p14 

    Presents a case study of heart disorders in a 46-year-old woman. Development of cardiotoxicity during treatment with quinidine for paroxysmal atrial fibrillation; Dosage of quinidine given to the patient; Factors that resolved the quinidine-induced cardiotoxicity.

  • Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction. Agusti, Antònia; Bonet, Sara; Arnau, Josep M.; Vidal, Xavier; Laporte, Joan-Ramon // Drug Safety;Sep2003, Vol. 26 Issue 12, p895 

    Background: The evidence-based benefit/risk evaluation of therapeutic interventions in randomised clinical trials should include both the assessment of the benefits and of the adverse outcomes. There is ample evidence that ACE inhibitors improve the symptoms and prognosis of chronic heart...

  • Trial Scorecards.  // Cardiology Today;Apr2009, Vol. 12 Issue 4, p8 

    The article presents summaries of the latest outcomes of various clinical trials in cardiology.

  • Clinical Trials in New Europe. DOIG, AL // Bio-IT World;Jan2009, Vol. 8 Issue 1, p13 

    The article presents an outlook for clinical trials in New Europe for 2009. The collapse of the Soviet Union is cited as one of the major factors which contributed to the emergence of new opportunity for clinical trials in Europe. An overview of the report from Insight Pharma Reports entitled...

  • Relevance of the clinical impact factor. Blitzkow, Gilson; Estrela, Carlos // Dental Press Endodontics;Jan-Apr2015, Vol. 5 Issue 1, p5 

    The author discusses the importance of systematic literature reviews to analyze clinical impact factors and select accurate and appropriate articles.

  • QUINIDINE SULFATE.  // International Pharmacopoeia: Fourth Edition;2006, Vol. 2, p816 

    A monograph for the pharmaceutical substance "QUINIDINI SULFAS/QUINIDINE SULFATE" from the fourth edition of "The International Pharmacopoeia" is presented. Quinidine sulfate is categorized as an antidysrhythmic drug and described as colourless and odourless, needle-like crystals or a white,...

  • Evaluation of Quinidine Short and Long-Acting in Control of Arrhythmias. Coodley, Eugene; Pugash, Neil; Toppo, Frank // Angiology;Sep1984, Vol. 35 Issue 9, p581 

    Twenty-one patients with arrhythmias responsive to quinidine were studied both with regard to consistency of response as determined by repeat Holter Monitoring and in half of these patients a comparison of short and long-acting quinidine was made. Holter Monitoring demonstrated greater than 60%...

  • The Role of Newer Antiarrhythmic Drugs in the Management of Patients with Ventricular Arrhythmias. Cain, Michael E. // Angiology;Jul1988 Part 2, Vol. 39 Issue 7, p668 

    The purpose of this review is to discuss the role of mexiletine, to-cainide, flecainide, and amiodarone in the treatment of patients with symptomatic ventricular ectopy or sustained ventricular tachycardia (VT) and fibrillation (VF). The pharmacologic properties, electrophysio-logic effects,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics